Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail aims to outsmart pancreatic cancer resistance

NCT ID NCT05077800

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 37 times

Summary

This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combination. The goal is to see if this approach improves how long the cancer stays under control compared to historical results with chemotherapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Massachusetts General Hospital

    Charlestown, Massachusetts, 02129, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

  • University of Washington School of Medicine

    Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.